Thank you Chanel5!
The BIEL "Coiled Spring": 8 Billion Potential Investors vs. One Regulatory Gate
There is a massive story developing behind the scenes with BIEL that the daily charts aren't showing yet. While the community is focused on the latest clinical data and the canine arthritis market, a huge "Liquidity Dam" has been built up by global regulations.
The Global "Lockout"
Right now, a group of dedicated overseas shareholders—who are also active product users—are literally unable to buy more shares.
They have the funds.
They have the brokerages.
They have the enthusiasm.
The Problem: Because $BIEL is currently "Pink Limited," international compliance filters and SEC Rule 15c2-11 have pulled the "Buy" button for millions of retail investors outside the US (and many inside).
The "8 Billion" Catalyst
Think about the math. We are looking at a potential global audience of 8 billion people who are currently barred from entering or increasing their positions.
The Barrier: It’s not the product; it’s the reporting status.
The Progress: The company recently (Nov 2025) verified its profile and has been active in adding top-tier talent like Sree Koneru, PhD, to the board. They are clearly cleaning house.
The Trigger: The second BIEL hits "Pink Current" status, the automated compliance blocks at international brokerages will start to drop.
Why This Matters
When a company goes from "Limited" to "Current," it doesn't just change a label—it re-opens the floodgates to global capital that has been sidelined for years.
We have a product that works (ActiPatch, RecoveryRx).
We have a massive new market (Veterinary/Canine).
We have a global shareholder base "dying to add" but currently restricted.
The Bottom Line: The current "Buy" restriction isn't a lack of interest; it’s a pent-up demand waiting for the financials to catch up. Once that gate opens, we aren't just looking at local interest—we're looking at the return of the global investor.
The BIEL "Coiled Spring": 8 Billion Potential Investors vs. One Regulatory Gate
There is a massive story developing behind the scenes with BIEL that the daily charts aren't showing yet. While the community is focused on the latest clinical data and the canine arthritis market, a huge "Liquidity Dam" has been built up by global regulations.
The Global "Lockout"
Right now, a group of dedicated overseas shareholders—who are also active product users—are literally unable to buy more shares.
They have the funds.
They have the brokerages.
They have the enthusiasm.
The Problem: Because $BIEL is currently "Pink Limited," international compliance filters and SEC Rule 15c2-11 have pulled the "Buy" button for millions of retail investors outside the US (and many inside).
The "8 Billion" Catalyst
Think about the math. We are looking at a potential global audience of 8 billion people who are currently barred from entering or increasing their positions.
The Barrier: It’s not the product; it’s the reporting status.
The Progress: The company recently (Nov 2025) verified its profile and has been active in adding top-tier talent like Sree Koneru, PhD, to the board. They are clearly cleaning house.
The Trigger: The second BIEL hits "Pink Current" status, the automated compliance blocks at international brokerages will start to drop.
Why This Matters
When a company goes from "Limited" to "Current," it doesn't just change a label—it re-opens the floodgates to global capital that has been sidelined for years.
We have a product that works (ActiPatch, RecoveryRx).
We have a massive new market (Veterinary/Canine).
We have a global shareholder base "dying to add" but currently restricted.
The Bottom Line: The current "Buy" restriction isn't a lack of interest; it’s a pent-up demand waiting for the financials to catch up. Once that gate opens, we aren't just looking at local interest—we're looking at the return of the global investor.
2
